Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Isracann Biosciences Inc. (C:IPOT)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 1600 - 595 Burrard Street
Tel: N/A
IR: See website
Key People
Business Overview
Isracann Biosciences Inc. is a Canada-based cannabis company. The principal business focus of the Company is medical cannabis cultivation and distribution to provide products to the Israeli medical cannabis market, and to develop and validate Natural Health Products (NHP), through the Company's operating subsidiaries. The Company's segments include Head Office, Medical Cannabis and Natural Health Product. The Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. The Company's subsidiaries include Isracann Holdings Inc., Praesidio Health Inc., Isracann Biosciences Capital Ltd., Isracann Operations Ltd., Isracann Development Ltd., Isracann Agritech Ltd., Isracann Administrative Services Ltd. and others.
Financial Overview
For the three months ended 31 August 2022, Isracann Biosciences Inc revenues was not reported. Net loss decreased 33% to C$316K. Lower net loss reflects Office facilities and administrative decrease of 87% to C$12K (expense), Consulting decrease of 27% to C$161K (expense), Promotion and advertising decrease from C$33K (expense) to C$0K.
Reporting Currency: Canadian Dollars
Enterprise value: $2.41M as of Aug 31, 2022
Annual revenue (TTM): $0.00M as of Aug 31, 2022
EBITDA (TTM): -$2.29M as of Aug 31, 2022
Net annual income (TTM): -$4.54M as of Aug 31, 2022
Free cash flow (TTM): -$1.48M as of Aug 31, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 175,228,944 as of Feb 1, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization